ArticleInternational journal of surgery (London, England)2026
The interrelationship between prostate cancer and osteoporosis: new perspectives on shared molecular pathways and treatment strategies.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is frequently regarded as a complication associated with androgen deprivation therapy (ADT) in patients with prostate cancer. Nevertheless, a notably higher incidence of osteoporosis has been observed in prostate cancer patients even in the absence of ADT, when compared to age-matched healthy individuals. This phenomenon is likely attributable to the synergistic effects of aging, chronic inflammation, and tumor-related factors, which collectively contribute to accelerated bone loss in this population. Accumulating evidence has demonstrated that signaling pathways such as RANKL/RANK/OPG, Wnt, CXCL12/CXCR4, TGF-β, and IGF-1, play critical roles in both prostate cancer and osteoporosis. These pathways may provide potential targets for the concurrent treatment of the two diseases. Despite this, existing reviews have provided only limited examination of the overlapping molecular mechanisms underpinning both diseases. This review aims to elucidate the interplay between osteoporosis and prostate cancer, offering a comprehensive analysis of the shared signaling pathways implicated in the progression of both conditions. In addition, prevailing treatment strategies for the prevention of osteoporosis in prostate cancer patients are evaluated, and the potential for the development of dual-action pharmacological agents targeting the RANKL/RANK/OPG, Wnt, and CXCL12/CXCR4 pathways is discussed. These emerging approaches may yield more effective therapeutic modalities for individuals with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.